Varespladib sodium is under clinical development by Ophirex and currently in Phase II for Poisoning. According to GlobalData, Phase II drugs for Poisoning have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Varespladib sodium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Varespladib sodium overview

A-001 (varespladib) is under development for snake bite. It was under development for the treatment of acute chest syndrome associated in sickle cell disease with vaso-occlusive crisis and acute organ failure (severe sepsis). The drug candidate is administered through intravenous route as infusion. It targets secretory phospholipase A2. sPLA2 belong to the family of secretory phospholipase enzyme, that are directly involved in the acute and chronic steps of an inflammatory response.

Ophirex overview

Ophirex, inc. (Ophirex) is a pharmaceutical company which is working to develop safe, effective, and accessible initial treatment for snakebite envenoming mostly in rural, impoverished areas. Ophirex is headquartered in Corte Madera, California, the US.

For a complete picture of Varespladib sodium’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.